Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD.

Neuro Oncol. 2009 Dec;11(6):853-60. doi: 10.1215/15228517-2009-010.

2.

Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.

Horak P, Wöhrer A, Hassler M, Hainfellner J, Preusser M, Marosi C.

J Neurooncol. 2012 Sep;109(2):323-30. doi: 10.1007/s11060-012-0896-2. Epub 2012 May 20.

PMID:
22610940
3.

Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.

Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ.

Gynecol Oncol. 2010 May;117(2):248-54. doi: 10.1016/j.ygyno.2010.01.002. Epub 2010 Feb 26.

PMID:
20189232
4.

Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Mazza E, Brandes A, Zanon S, Eoli M, Lombardi G, Faedi M, Franceschi E, Reni M.

Cancer Chemother Pharmacol. 2016 Jan;77(1):115-20. doi: 10.1007/s00280-015-2927-0. Epub 2015 Dec 11.

PMID:
26659583
5.

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ; European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

J Clin Oncol. 2008 Oct 1;26(28):4659-65. doi: 10.1200/JCO.2008.16.9235.

6.

Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.

Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, Huvos AG, Sowers R, Meyers PA, Healey JH, Gorlick R.

Cancer. 2008 May 15;112(10):2119-29. doi: 10.1002/cncr.23437.

7.

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS.

J Neurooncol. 2012 Jan;106(2):409-15. doi: 10.1007/s11060-011-0687-1. Epub 2011 Sep 22.

8.
9.

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD.

Clin Cancer Res. 2006 Aug 15;12(16):4899-907.

10.

Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.

Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC.

J Thorac Oncol. 2009 Oct;4(10):1270-3. doi: 10.1097/JTO.0b013e3181b6be57.

11.

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC.

J Clin Oncol. 2008 Jul 10;26(20):3418-25. doi: 10.1200/JCO.2007.14.3420.

PMID:
18612157
12.

Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.

De Pas T, Toffalorio F, Colombo P, Trifirò G, Pelosi G, Vigna PD, Manzotti M, Agostini M, de Braud F.

J Thorac Oncol. 2008 Aug;3(8):938-41. doi: 10.1097/JTO.0b013e3181803f08.

13.

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.

Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM.

Gynecol Oncol. 2012 Jun;125(3):640-5. doi: 10.1016/j.ygyno.2012.02.034. Epub 2012 Feb 28.

PMID:
22387451
14.

Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.

Gupta V, Samuleson CG, Su S, Chen TC.

Neurosurg Focus. 2007;23(4):E9.

PMID:
17961046
15.

Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.

Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN.

Ann Oncol. 2008 Oct;19(10):1713-9. doi: 10.1093/annonc/mdn352. Epub 2008 May 29.

16.

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr, Morton RF, Schild SE, Jett JR, Adjei AA.

Ann Oncol. 2005 Nov;16(11):1811-6. Epub 2005 Aug 8.

PMID:
16087693
17.

Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.

Koon HB, Krown SE, Lee JY, Honda K, Rapisuwon S, Wang Z, Aboulafia D, Reid EG, Rudek MA, Dezube BJ, Noy A.

J Clin Oncol. 2014 Feb 10;32(5):402-8. doi: 10.1200/JCO.2012.48.6365. Epub 2013 Dec 30.

18.

A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.

Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, Worden FP.

Thyroid. 2010 Sep;20(9):975-80. doi: 10.1089/thy.2010.0057.

19.

Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.

Huang CH, Williamson SK, Van Veldhuizen PJ, Hsueh CT, Allen A, Tawfik O, Wick J, Smith H, Uypeckcuat AM, Mayo M, Kelly K.

J Thorac Oncol. 2011 Feb;6(2):372-7. doi: 10.1097/JTO.0b013e318200f9ad.

20.

Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.

Saito S, Nakata K, Kajiura S, Ando T, Hosokawa A, Sugiyama T.

Digestion. 2013;87(1):47-52. doi: 10.1159/000343938. Epub 2013 Jan 21.

Supplemental Content

Support Center